National Survey on Hypertension in Cardiologic Private Practice (Prophyl C)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00695175
First received: June 9, 2008
Last updated: August 4, 2009
Last verified: August 2009
  Purpose

To evaluate (with sufficient accuracy) the profile(demographic and clinical characteristics, health care management) of hypertensive patients seen in private cardiology consultation by holding account of type of exercise of the cardiologist (private exclusive or mixed hospital and private).


Condition
Hypertension

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Profile of Hypertensive Patients Seen in Private Cardiology Consultation

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Demographic, clinical and health care characteristics [ Time Frame: Once ]

Enrollment: 1800
Study Start Date: February 2008
Study Completion Date: September 2008
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First three consecutive patients with hypertension seen by Cardiologists

Criteria

Inclusion Criteria:

  • male or female > or = 18 years old
  • Known hypertension
  • agree to take part in this study

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00695175

  Show 436 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne, Medical Director AstraZeneca
  More Information

No publications provided

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00695175     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2007/6
Study First Received: June 9, 2008
Last Updated: August 4, 2009
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Hypertension
Private cardiology consultation
Patients with hypertension

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 19, 2014